We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Glatiramer acetate induces mast cell degranulation via MRGPRX2, implications for local and systemic adverse reactions.
- Authors
Chaki, Shaswati; Amponnawarat, Aetas; Levenstein, Brett; Hui, Yvonne; Oskeritzian, Carole; Ali, Hydar
- Abstract
Glatiramer acetate (GA) is a drug used to treat relapsing-remitting multiple sclerosis (RRMS), but it can cause adverse reactions such as injection site reactions (ISRs) and immediate post-injection systemic reactions (IPISR). This study found that GA induces mast cell degranulation, which may contribute to these adverse effects. The researchers discovered that GA activates mast cells through the Mas-related G protein-coupled receptor X2 (MRGPRX2). Inhibitors of MRGPRX2 could potentially be used to prevent adverse reactions in RRMS patients. This finding also suggests that GA's inhibition of T cell responses and its induction of mast cell degranulation may have implications for the treatment of RRMS.
- Subjects
GLATIRAMER acetate; MAST cells; CELL receptors; STEM cell factor; G protein coupled receptors; MAST cell disease
- Publication
Allergy, 2024, Vol 79, Issue 3, p758
- ISSN
0105-4538
- Publication type
Article
- DOI
10.1111/all.15978